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Toxin synergism in snake venoms 
Synergism between venom toxins exists for a range of snake species. Synergism 
can be derived from both intermolecular interactions and supramolecular 
interactions between venom components and can be the result of toxins targeting 
the same protein, biochemical pathway, or physiological process. Few simple 
systematic tools and methods for determining the presence of synergism exist, 
but include co-administration of venom components and assessment of 
Accumulated Toxicity Scores. A better understanding of how to investigate 
synergism in snake venoms may help unravel strategies for developing novel 
therapies against snakebite envenoming by elucidating mechanisms for toxicity 
and interactions between venom components. 
Keywords: Toxin synergism, intermolecular synergism, supramolecular 
synergism, Toxicity Score, snake venom, snake toxins, Accumulated Toxicity 
Score. 
1. Introduction  
Producing and replenishing venom comes with a metabolic cost for snakes 
(Morgenstern and King, 2013). This metabolic cost can, however, be lowered through 
toxin synergism, which may allow a venom to reach high potency with less toxins. 
According to the Oxford Dictionaries, synergism is “the interaction or cooperation of 
two or more organizations, substances, or other agents to produce a combined effect 
greater than the sum of their separate effects” 
(http://www.oxforddictionaries.com/definition/english/synergy). Within toxinology, 
synergism arises when a venom displays a much higher toxicity than the sum of the 
toxicities for the individual venom components, which may possibly provide an 
evolutionary advantage. Toxin synergism has been studied and reported for snakes, 
spiders, and scorpions (Lauridsen et al., 2016, Strydom, 1976, Wullschleger et al., 1998, 
Chan et al., 1975, Lazarovici et al., 1984), whose venoms have evolved to subdue prey 
and deter predators and competitors (Barlow et al., 2009, King et al., 2011). Due to its 
inherent complexity, synergism is difficult to study, and to the best of my knowledge, 
no common framework or method exists for determining the presence of synergism in a 
venom. Also, limited agreement on how to classify types of synergism and distinguish 
between synergism and auxiliary effects exists in the scientific literature. In this review, 
a distinction between synergism and auxiliary effects will be discussed, the different 
types of synergism that have been reported for snake venoms will be reviewed, and 
existing tools and methods for determining the presence of synergism in venoms and 
toxin mixtures will be presented. This review will thus help provide an overview of 
toxin synergism in snake venoms and provide guidance on how to study the 
phenomenon. 
 
2. Synergism vs. auxiliary effects 
The difference between toxin synergism and auxiliary effects could be viewed as the 
difference between potentiating and facilitating toxic effects in an envenomed victim. 
Auxiliary effects could thus be defined as effects of venom components that do not 
contribute directly to venom toxicity, but instead have other functions for supporting 
toxicity, such as modifying venom delivery, half-life, and distribution (Figure 1). As an 
example of auxiliary effects, adenosine is often found in snake venoms (Aird, 2002), 
where its vasodilatory effects may increase blood perfusion at the site of envenoming. 
This leads to an increased rate of systemic venom distribution in the victim, but not 
necessarily to an increase in venom toxicity. Also, hyaluronidases in snake venoms may 
primarily have a supportive function by increasing the distribution rate of venom 
components through degradation of hyaluronic acid in the extracellular matrix 
(Kemparaju and Girish, 2006). As an example, the toxicity of the venom of Crotalus 
durissus terrificus (South American rattlesnake) has been shown to be dependent on 
facilitated distribution of crotoxin and other phospholipases A2 (PLA2s) by 
hyaluronidases with no toxicity themselves (Bordon et al., 2012). This shows that 
auxiliary effects may in some cases be crucial for the ability of a venom to exert its 
toxic functions, although the proteins responsible for the auxiliary effects do not 
increase the toxicity of any of the venom toxins per se. In contrast to these examples, 
synergistic effects directly contribute to increased toxicity, and the venom components 
that act synergistically usually have a toxic effect on the same or related physiological 
targets or pathways or interact with and potentiate the effects of a key toxin. 
 
3. The different types of synergism occurring in snake venoms 
Following the above, synergism is the phenomenon where two or more venom 
components interact directly or indirectly to potentiate toxicity to levels above the sum 
of their individual toxicities. From a molecular perspective, synergism may exist in two 
general forms: 
 
(1) Intermolecular synergism, when two or more toxins interact with two or more 
targets on one or more (related) biological pathways, causing synergistically 
increased toxicity (Figure 2A, B). 
(2) Supramolecular synergism, when two or more toxins interact with the same 
target in a synergistic manner (Figure 2C) or when two or more toxins associate 
and create a complex with increased toxicity (Figure 2D).  
 
3.1 Intermolecular synergism 
Intermolecular synergism may exist in several forms, where toxins may either act on 
different targets of a physiological process causing a combined synergistic effect 
(Figure 2A) or different physiological processes, which subsequently affect another 
process further downstream in a synergistically enhanced manner (Figure 2B). An 
example of the first case is illustrated by the venom of Dendroaspis polylepis (black 
mamba), which has been shown to display synergism (Strydom, 1976). This synergism 
is possibly created by dendrotoxins exerting an excitatory effect on the neuromuscular 
system, combined with a rapid abrogation of neuromuscular function by α-neurotoxins 
(Laustsen et al., 2015A). Combined, these toxins cause a synergistic potent toxic effect 
leading to flaccid paralysis and respiratory failure in victims and prey. In contrast to 
these examples, synergistic behaviour is not observed for the neurotoxic venom of Naja 
kaouthia (monocled cobra), which may be due to the fact that the α-neurotoxins 
dominating the venom all target the same receptor (Tan et al., 2015, Laustsen et al., 
2015B). Instead of causing synergistic action, the α-neurotoxins compete with each 
other for the target, causing additive, but not synergistic effects (Figure 2E). Similarly, 
additive effects have been reported for venom toxins from the elapids hemachatus 
haemachatus, Naja nigricollis, N. melanoleuca, N. haje, N. nivea, D. polylepis, and D. 
jamesoni (Viljoen and Botes, 1973). 
An example of synergism arising through a combined effect of toxins targeting 
different pathways (Figure 2B) is reported by Chen and co-workers. Chen et al. suggest 
that the actions of L-amino acid oxidases combined with the actions of other venom 
components of Daboia russelii (Russell’s viper) venom cause prolonged and enhanced 
bleeding in envenoming cases by this viper species (Chen et al., 2012). Other 
synergistically acting toxins affecting blood coagulation are known to exist. Prominent 
examples include the prothrombin activators from group B (Ca2+-dependent 
metalloproteinases found in viper venoms) and the prothrombin activators group C 
(serine proteinases found exclusively in Australian elapids) (Kini et al., 2001). These 
prothrombin activators exert their function via proteolytic activation of prothrombin to 
mature thrombin (Kini, 2005), which may combine with other toxin-induced 
coagulopathies causing synergistically enhanced toxicity. 
Another example of toxin synergism is provided by the ‘Asp49’ and ‘Lys49’ 
myotoxins of Bothrops asper (Fer-de-lance), which combined cause synergistic 
myonecrotic effects in vitro and in vivo (Mora-Obando et al., 2014). These types of 
myotoxins have been shown to increase plasma membrane Ca2+ permeability, causing 
rapid cell death for myotubes (Cintra-Francischinelli et al., 2009), which is a scenario 
that is conceptually similar to Figure 2C. Synergism may also appear when toxins from 
different venoms are mixed. This is exemplified by the venoms of Dienagkistrodon 
acutus (sharp-nosed viper) and Agkistrodon halys (Siberian pit viper), which in 
combination produce synergistic procoagulation effects on dog plasma (Wei et al., 
1996). 
 
3.2 Supramolecular synergism 
Supramolecular synergism may arise when toxins form complexes with 
synergistic effects via a mechanism conceptually similar to Figure 2D, in which several 
venom components combine to create a hyper-potentiated toxin. An example of such 
synergistic enhancement includes cytotoxins from different cobra species. Cobra 
cytotoxins have been shown to enhance PLA2 activity through complex formation and 
deformation of cell membranes, causing cellular lysis due to hydrolysis of 
phospholipids (Gasanov et al., 1997, Gasanov et al., 2014). On a more toxin-specific 
level, Chaim-Matyas et al. (1995) showed that cytotoxin P4 from Naja nigricollis 
(black-necked spitting cobra) venom acted synergistically with various PLA2s when 
cancer cell lines were subjected to these toxins in vitro, causing cell lysis. Similar 
synergistic effects on cellular and subcellular membranes have been observed for a 
range of other cell types, including erythrocytes, liver mitochondria, and platelets 
(Condrea, 1974). 
In contrast to these examples of synergism, some snake venoms have evolved to 
have different potent effects, which do not necessarily interact in a synergistic manner. 
Herrera et al. (2012) showed that the venom of Oxyuranus scutellatus (coastal taipan) 
displays strong presynaptic neurotoxicity at low doses, while the clinical manifestations 
at high doses include intravascular thrombosis due to the presence of prothrombin 
activators. Instead of displaying synergism, these two venom effects seem to constitute 
a dual strategy, where the two effects complement each other rather than enhance the 
toxicity of the counterpart (conceptually similar to Figure 2F). However, in addition to 
having non-synergistic toxic functions working in parallel, the venom of O. scutellatus 
also displays supramolecular synergism. This supramolecular synergism is observed for 
the presynaptic neurotoxin, taipoxin (Fohlman et al., 1976), which is assembled by three 
homologous phospholipase A2 subunits (Montecucco and Rossetto, 2008), and the 
calcium channel inhibitor, taicatoxin, which is assembled by an 8 kDa -neurotoxin-
like peptide, a 16 kDa neurotoxic PLA2, and four 7 kDa serine protease inhibitors 
through non-covalent bonding (Possani et al., 1992). Similar to taipoxin and taicatoxin, 
the presynaptic neurotoxin textilotoxin from another Australian elapid (Pseudonaja 
textilis, eastern brown snake) displays supramolecular synergism via oligomerization 
(see Figure 2D). Textilotoxin is assembled by five homologous PLA2 subunits, whereby 
the toxicity of subunit A (Pearson et al., 1991) is hyper-potentiated (Montecucco and 
Rossetto, 2008). It has been suggested that the synergistic effects for such presynaptic 
neurotoxin complexes from elapids derive from their enhanced ability to localize in the 
synapse facilitated by non-toxic PLA2 subunits (Rigoni et al., 2005). An equivalent 
example is also present in viper venom. Crotoxin from the venom of the South 
American rattlesnake (Crotalus durissus terrificus) exists in different structural 
isoforms and is a heterodimeric toxin complex formed by an acidic PLA2 (subunit A) 
devoid of toxicity and a basic PLA2 (subunit B) of low toxicity (Bon et al., 1979, Faure 
and Bon, 1988). Following complexation, subunit A synergistically enhances the 
potency of subunit B (Choumet et al., 1999), causing its lethal neurotoxic effects (Bon 
et al., 1988) (see Figure 2D). 
Supramolecular synergism has also been reported for the two three-finger toxins, 
hemextin A and hemextin B, from the African Ringhals cobra (Hemachatus 
haemachatus). These two toxins combine to form a hemextin AB complex, which 
inhibits the TF.VIIa complex formed between freshly exposed tissue factor and factor 
VIIa, thereby synergistically abrogating the formation of blood clots (Banerjee et al., 
2005, Kini, 2006, Kini, 2011) (conceptually similar to Figure 2D). Opposite 
procoagulant effects are observed for the prothrombin activator, Pseutarin C, from P. 
textilis venom, which is formed by dimerization of an enzymatic and a non-enzymatic 
subunit (Rao and Kini, 2002), highlighting the diverse range of synergistic effects that 
can be achieved through supramolecular interactions. 
Another example of supramolecular synergism is likely to exist for the venom of 
D. jamesoni (Jameson’s mamba). In this venom, the component S2C4 with relatively 
low toxicity interacts with angusticeps-type toxins in a synergistic manner when both 
toxins are co-administered in vivo (Joubert and Taljaard, 1979). In comparison, Strydom 
and Botes (1970) showed that separated venom fractions from the venom of the related 
D. angusticeps (Eastern green mamba) were devoid of lethality after 48 hours when 
administered alone, whereas the whole venom was lethal within 10 minutes when 
administered at a similar dose. Finally, non-toxic Kunitz-type inhibitors have been 
shown to interact with ammodytoxins in the venom of Vipera ammodytes ammodytes 
(Horned viper) (Brgles et al., 2014) and PLA2s in the venom of Micrurus tener (Texas 
coral snake) in order to create complexes of increased toxicity (Bohlen et al., 2011, 
Olivera and Teichert, 2011). A wealth of other examples of how venom components 
combine to create toxins with potent effects occur in Nature, and a comprehensive 
review on protein complexes in snake venoms can be found here (Doley and Kini, 
2009). 
 
4. Determining the presence of synergism 
Few standardized methods are used to determine the presence of synergism between 
toxins in venoms. However, in the scientific literature, two fundamentally different 
approaches have been reported. One focuses on the observed toxicity when selected 
components are co-administered in vitro or in vivo, whereas the other is based on a 
toxicovenomic approach (Calvete and Lomonte, 2015) involving an assessment of 
toxicities and abundancies of all venom components.  
 
4.1 Co-administration of venom components 
An example provided by Strydom involves the co-administration of two venom 
fractions in different doses and comparing the observed toxicities with the toxicity 
observed when each component is administered individually. In his work, he 
demonstrated that fractions F and I from the venom of D. polylepis combined showed 
significantly increased toxicity, despite only having low toxicities on an individual basis 
(Strydom, 1976). The author (2015A) employed a similar method for detection of 
synergism between toxins from D. polylepis. In this method, a constant (sub-lethal) dose 
of a single venom component is co-administered, while the LD50 of another venom 
component is determined. If the LD50 of the second component is significantly lowered 
by the presence of the sub-lethal dose of the first component, synergism may be present. 
We were however not able to detect synergism between short neurotoxin 1 and 
dendrotoxins in the venom of D. polylepis following this method (Laustsen et al., 
2015A). However, in later work performed on the venom of D. angusticeps, synergism 
was detected by this method between components present in fractions 4-12 of the 
venom (Lauridsen et al., 2016), supporting the previous observation by Joubert and 
Taljaard (1979). 
Co-administration experiments have the benefit that they can elucidate direct 
synergistic interactions between selected components. However, the drawback of such 
experiments is that they require laborious experimentation and optimization in order to 
yield useful results. When synergism is investigated using an in vivo test, this 
disadvantage also comes with a concern of how many experimental animals it is ethical 
to employ (and thus sacrifice) in such studies. 
 
4.2 Accumulated Toxicity Score 
Another approach for establishing the presence of synergism in venoms involves a more 
holistic approach based on the Toxicity Score. The Toxicity Score for a given toxin is 
calculated by dividing the lethality (LD50) of a toxin with its relative abundance in the 
venom from which the toxin is derived (Laustsen et al., 2015C). The Toxicity Scores of 
different toxins in a venom can then be used to index the toxins according to their 
relative importance in an envenoming case, which may be useful for determining which 
toxins are essential to neutralize with antivenom, and which are not. In addition to its 
usefulness in determining which toxins are the medically most important in a venom, 
the use of the Toxicity Score for establishing whether a venom displays synergism has 
recently been reported (Lauridsen et al., 2016, Laustsen et al., 2015C). In these cases, it 
was shown that the Toxicity Scores of the whole venoms of Dendroaspis angusticeps 
and Aipysurus laevis were much larger than the sum of the Toxicity Scores of the 
individual toxins, indicating that the toxins present in these venoms act in a synergistic 
manner.  The presence of synergism can thus be determined, when the Toxicity Score of 
the whole venom is significantly larger than the sum of the Toxicity Scores for 
individual toxins (or venom fractions), termed the Accumulated Toxicity Score:  
 
𝑇𝑜𝑥𝑖𝑐𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒𝑊ℎ𝑜𝑙𝑒 𝑣𝑒𝑛𝑜𝑚 > ∑ 𝑇𝑜𝑥𝑖𝑐𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒𝑇𝑜𝑥𝑖𝑛 𝑋
𝑇𝑜𝑥𝑖𝑛 𝑛
𝑇𝑜𝑥𝑖𝑛 1   (I) 
 
Examples of how the Accumulated Toxicity Score can be employed to determine the 
presence or absence of synergism are provided in Table 1. 
Due to limitations on what type of toxins that can be assessed using the Toxicity 
Score, this approach can only be readily employed for determining the presence of 
synergism in venoms from elapid snake species and where toxic effects culminate in 
lethality. The approach applies well to these venoms, since they are lethal, and since 
their toxins are generally not denatured during isolation and purification (Laustsen et 
al., 2015C). For other species (such as viperid snakes, spiders, centipedes, jellyfish etc.) 
the approach is compromised by the fact that the severity of envenoming cannot purely 
be judged by lethality, but also has to take account of other toxic effects, such as 
necrosis, coagulopathy, and systemic hemorrhage (Warrell, 2010), and since many of 
the medically relevant toxins (such as metalloproteinases) are easily denatured during 
their isolation (Laustsen et al., 2015C). Additionally, this simple approach may 
potentially also be useful for scorpion venoms, which are generally characterized by 
being neurotoxic (Goyffon and Tournier, 2014), but it is unlikely to be useful for 
venoms from various other species, whose toxins are either easily denatured (jellyfish) 
(Endean, 1987) or whose venoms are devoid of lethal effects in relevant model animals 
(centipedes and most spiders) (Undheim et al., 2014, Sannaningaiah et al., 2014). 
A drawback of using the Accumulated Toxicity Score for determining the 
presence of synergism compared to the approach involving co-administration of 
individual venom components is that it does not specify between which components 
synergism exists. Combined, the initial use of the Accumulated Toxicity Score may, 
however, unveil if a venom displays synergism, which can then be followed up with co-
administration approaches in the relevant cases to determine the exact components 
responsible for the observed synergism. 
 
5. Conclusion 
Toxin synergism is a fascinating phenomenon, which has been shown to occur in many 
different snake venoms. The phenomenon is still poorly investigated and understood 
due to its inherent complexity. The importance of being able to determine the presence 
of synergism and having a mechanistic model for how venoms exert their toxic effects 
is, however, becoming increasingly more important driven by a trend in antivenom 
development where biotechnological approaches are being employed to identify specific 
antitoxins targeting individual toxins of medical importance (Roncolato et al., 2015, 
Richard et al., 2013, Chavanayarn et al., 2012, Laustsen et al., 2016A, Laustsen et al., 
2016B, Carmo et al., 2015). Therefore, when selecting which toxin targets to focus on, 
it is important to focus both on toxins that are medically relevant on an individual basis 
(Laustsen et al., 2015C) and on potential non-toxic venom components, which may 
enhance the effect of other components through synergism (Lauridsen et al., 2016). The 
current tools and methods used for assessing toxin synergism in snake venoms are few, 
but may be utilized to obtain a better understanding of how to develop novel snakebite 
envenoming therapies targeting key toxins involved in synergistically enhanced 
toxicity. 
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Table 1. Overview of Toxicity Scores for toxins (venom fractions) and whole venoms 
from all reported toxicovenomic studies. 
 
Species 
Toxicity Score 
(whole venom) 
 Accumulated 
Toxicity Score* 
Synergism Reference 
Dendroaspis 
polylepis 
147.1 > 127.8 Yes 
Laustsen et al., 
2015A 
Dendroaspis 
angusticeps 
117.6 > 62.6 Yes 
Lauridsen et al., 
2016 
Naja kaouthia 423.2 ≈ 419.7 No 
Laustsen et al., 
2015B 
Aipysurus 
laevis 
676 > 355.8 Yes 
Laustsen et al., 
2015D 
*In the determination of this value, only calculated Toxicity Scores have been included. Toxins with 
Toxicity Scores below the chosen threshold for relevant toxicity in the toxicovenomic study have thus 
been excluded. For D. polylepis, N. kaouthia, and A. laevis this threshold was generally when the Toxicity 
Score was < 1. For D. angusticeps, the threshold was when the Toxicity Score was < 7. 
 
  
Figure 1: Schematic representation of the differences between auxiliary effects and 
toxin synergism. A) Envenoming without auxiliary effects and without toxin synergism: 
All mice survive envenoming after 10 minutes, whereas some mice die after 24 hours. 
B) Envenoming with auxiliary effects but without toxin synergism: The onset of the toxic 
effects of envenoming is advanced, but toxicity remains similar to A). C) Envenoming 
without auxiliary effects but with toxin synergism: Onset of envenoming is similar to A), 
however, toxicity is higher, leading to an increased number of deaths after 24 hour. The 
time intervals (10 min and 24 hours) are chosen solely for illustrative purposes. 
 
 
Figure 2: Schematic representation of theoretical scenarios in which synergism 
between toxins occur (A, B, C, and D), and do not occur (E and F). A) When toxins 
target different targets on the same physiological pathway, this may create a synergistic 
effect due to amplification. B) When toxins target different pathways, which all regulate 
or interact with another physiological pathway, this may create a synergistic effect due 
to amplification. C) When toxins target the same target in a cooperative manner, 
synergism may occur. D) When toxins combine to form an oligomeric toxin that has a 
toxicity, which is higher than the combined toxicities of the individual components, 
synergism occurs. E) When toxins target the same target in a competitive manner, 
synergism does not occur. F) When toxins target different pathways, which are 
unrelated, synergism does not occur. The colors do not specify any particular class of 
toxins or targets, but they are only provided to illustrate that the toxins and targets are 
different from each other.    
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